ArticleDrugs2009
Emerging treatments in cystic fibrosis.
Article in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 113 citations in OpenAlex.
- Inhaled nucleic acid delivery systems for the treatment of pulmonary interstitial diseases: Challenges and opportunities.Acta pharmaceutica Sinica. B · 2026Review
- A Novel 7ACS medicinal chemistry letters · 2023Article
- Article
- Synthesis, X-ray diffraction analysis, quantum chemical studies andJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents.Molecules (Basel, Switzerland) · 2022Review
- Design, synthesis and cytotoxic evaluation of a library of oxadiazole-containing hybrids.RSC advances · 2021Article
- Synthesis of 5-arylacetylenyl-1,2,4-oxadiazoles and their transformations under superelectrophilic activation conditions.Beilstein journal of organic chemistry · 2021Article
- Metal Complexes of Oxadiazole Ligands: An Overview.International journal of molecular sciences · 2019Review
- Cystic fibrosis disease severity correlates with plasma levels of desmosine and isodesmosine, biomarkers of elastin degradation.ERJ open research · 2019Article
- Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation.Frontiers in pharmacology · 2019Article
- PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model.Oncology letters · 2018Article
- Genetic architecture: the shape of the genetic contribution to human traits and disease.Nature reviews. Genetics · 2018Review
- Induction of CFTR gene expression by 1,25(OH)The Journal of steroid biochemistry and molecular biology · 2017Article
- Mathermycin, a Lantibiotic from the Marine Actinomycete Marinactinospora thermotolerans SCSIO 00652.Applied and environmental microbiology · 2017Article
- Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.Chemical reviews · 2017Review
- Insights into the Biosynthesis of Duramycin.Applied and environmental microbiology · 2017Article
- Metal-free hydroarylation of the side chain carbon-carbon double bond of 5-(2-arylethenyl)-3-aryl-1,2,4-oxadiazoles in triflic acid.Beilstein journal of organic chemistry · 2017Article
- Characterization of the stereochemical configuration of lanthionines formed by the lanthipeptide synthetase GeoM.Biopolymers · 2016Article
- The many roles of glutamate in metabolism.Journal of industrial microbiology & biotechnology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are a number of potential drugs for the treatment of cystic fibrosis (CF) currently undergoing clinical studies. A number of antibacterials formulated for delivery by inhalation are at various stages of study; these include dry-powder inhaler versions of colistin, tobramycin and ciprofloxacin, and formulations of azteonam, amikacin, levofloxacin, ciprofloxacin and fosfomycin/tobramycin for nebulization. Clinical trials of anti-inflammatory agents, including glutathione, phosphodiesterase-5 inhibitors such as sildenafil, oral acetylcysteine, simvastatin, methotrexate, docosahexaenoic acid, hydroxychloroquine, pioglitazone and alpha1-antitrypsin, are ongoing. Ion channel modulating agents, such as lancovutide (Moli1901, duramycin) and denufosol, which activate alternate (non-CF transmembrane regulator [CFTR]) chloride channels, and GS 9411, a sodium channel antagonist, are now at the stages of clinical study and if successful, will offer a new category of therapeutic agent for the treatment of CF. Correction of the underlying gene effect, either by agents that help to correct the dysfunctional CFTR, such as ataluren, VX-770 and VX-809, or by gene transfer (gene therapy), is a particularly exciting prospect as a new therapy for CF and clinical studies are ongoing. This article reviews the exciting potential drug treatments for CF currently being evaluated in clinical studies, and also highlights some of the challenges faced by research and clinical teams in assessing the efficacy of potential new therapies for CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.